CMMB — CHEMOMAB THERAPEUTICS LTD
As of Q2 2026, 2 SEC-registered investment managers reported holding CMMB (CHEMOMAB THERAPEUTICS LTD) in their latest 13F filings, with a combined reported value of $160.20K across 98.89K shares. That is +43.8% by share count (+30.12K shares) versus the previous quarter, while reported value moved +48.4%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 added to existing stakes, 1 trimmed, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
CMMB is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Citadel Advisors history | Q2 2026 | 95.31K | $154.40K | 0.00% | Add |
| Renaissance Technologies history | Q1 2022 | 27.96K | $134.00K | 0.00% | New |
| Two Sigma Investments history | Q2 2024 | 24.39K | $22.26K | 0.00% | Reduce |
| Millennium Management history | Q3 2024 | 10.56K | $16.59K | 0.00% | New |
| Geode Capital Management history | Q2 2024 | 11.74K | $10.80K | 0.00% | Hold |
| Morgan Stanley history | Q2 2026 | 3.58K | $5.79K | 0.00% | Reduce |
| ARK Invest history | Q1 2022 | 792 | $4.00K | 0.00% | Reduce |
| JPMorgan Chase & Co history | Q2 2025 | 1.18K | $1.37K | 0.00% | New |
| UBS Group AG history | Q1 2026 | 8 | $13 | 0.00% | Reduce |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
- UBS Group AG sold 8 sh · $13
Fund Position History — shares by quarter (top 9 funds)
| Fund | Q3 2021 | Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citadel Advisors | — | — | — | — | 21.23K | — | — | — | — | 32.68K | — | 62.40K | — | — | — | — | — | 103.78K | 64.18K | 95.31K |
| Morgan Stanley | 95 | 11.64K | — | 5.59K | 6.20K | 6.60K | 7.80K | 100 | — | 70.92K | 2.80K | 7.20K | 402.27K | 104.40K | 117.16K | 1.61M | 90.06K | 3.77K | 4.58K | 3.58K |
| UBS Group AG | 1.75K | 1.84K | 885 | — | 4.89K | 4.63K | 411 | 12 | 141 | — | — | — | 2.29K | 485 | 883 | 397 | 99 | 2.25K | 8 | — |
| ARK Invest | 180.52K | 267.29K | 792 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| JPMorgan Chase & Co | — | — | 753 | — | — | — | — | — | — | — | 1 | 1 | 1.10K | — | — | 1.18K | — | — | — | — |
| Renaissance Technologies | — | — | 27.96K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Two Sigma Investments | — | — | — | — | — | — | 30.26K | — | — | 56.30K | 39.99K | 24.39K | — | — | — | — | — | — | — | — |
| Geode Capital Management | 13.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | 11.74K | — | — | — | — | — | — | — | — |
| Millennium Management | — | — | — | — | — | — | — | — | — | 19.70K | — | — | 10.56K | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details